<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>DT-IMMZ.D5.DT.TBEcontraindications</title><link rel="stylesheet" type="text/css" href="includes/dmn.css" /></head><body><table xmlns="" class="decision"><tr class="decision-header"><td class="row-label">Decision ID</td><td colspan="100"><span class="decision-id">DT-IMMZ.D5.DT.TBEcontraindications</span><span class="decision-name">DT-IMMZ.D5.DT.TBEcontraindications</span></td></tr><tr class="io-row"><td class="row-label">Inputs/Outputs</td><td class="input">Potential contraindications</td></tr><tr class="rule"><td class="row-label"></td><td class="inputEntry">
          "Potential contraindications" = "Currently pregnant"
          The client is currently pregnant
        </td><td class="outputEntry">
          "Immunization recommendation status" = "Further evaluation needed"
          Clinical judgement is required. Create a clinical note
        </td><td class="outputEntry">
          Conduct a risk–benefit assessment considering the incidence of the disease,  consider risks of vaccination and make a clinical judgement.
          Conduct a risk–benefit assessment considering the incidence of the disease, consider risks of vaccination and make a clinical judgement.
        </td><td class="annotationEntry">
          The vaccine should be used in pregnant women who live in areas where the incidence of the disease is high (&gt; 5 cases/100 000 population per year). In areas where the incidence is moderate or low (&lt; 5/100 000 population per year), the risks and benefits of the vaccine should be considered (e.g. health professionals should assess whether a pregnant woman participates in outdoor activities that increase her risk of the disease).
        </td><td class="annotationEntry">
          Vaccines against tick-borne encephalitis: WHO position paper (June 2011) (19)
        </td><td class="annotationEntry">
          The vaccine should be used in pregnant women who live in areas where the incidence of the disease is high (&gt; 5 cases/100 000 population per year). In areas where the incidence is moderate or low (&lt; 5/100 000 population per year), the risks and benefits of the vaccine should be considered (e.g. health professionals should assess whether a pregnant woman participates in outdoor activities that increase her risk of the disease).
        </td><td class="annotationEntry">
          Vaccines against tick-borne encephalitis: WHO position paper (June 2011) (19)
        </td></tr><tr class="rule"><td class="row-label"></td><td class="inputEntry">
          "Potential contraindications" = "Moderate to severe fever"
          The client has moderate to severe fever
        </td><td class="outputEntry">
          "Immunization recommendation status" = "Further evaluation needed"
          Clinical judgement is required. Create a clinical note
        </td><td class="outputEntry">
          Consider postponing the vaccination if the client has fever &gt; 38.5°C or other signs of serious disease. Consider risks of vaccination and make a clinical judgement.
          Consider postponing the vaccination if the client has fever &gt; 38.5°C or other signs of serious disease. Consider risks of vaccination and make a clinical judgement.
        </td><td class="annotationEntry">
          –
        </td><td class="annotationEntry">
          –
        </td></tr></table></body></html>